In the September 9 cover article of Cancer Cell, researchers integrated 10x single cell and spatial technologies to identify a mechanism of glioblastoma recurrence in mice and develop a promising potential therapeutic approach.

PLEASANTON, Calif., Sept. 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that its Chromium Single Cell Gene Expression and Xenium In Situ platforms were used in a publication – featured on the cover of Cancer Cell – that sheds light on the role of fibrotic scars in glioblastoma treatment recurrence. The study, led by researchers in the laboratory of Professor Johanna Joyce (University of Lausanne, Switzerland) and the Ludwig Institute for Cancer Research (Lausanne, Switzerland), also showcased how inhibiting both colony stimulating factor 1 receptor (CSF-1R; a therapeutic target under investigation for treating multiple cancers, including glioblastoma (GBM)) and the formation of fibrotic scars led to improved survival of mice in preclinical trials.